Pharmaceutical companies cut investments in Germany, government defends course

The German federal government has responded to announcements from pharmaceutical giants Boehringer Ingelheim and Eli Lilly regarding substantial reductions in their planned investments within Germany. A spokesperson for the Federal Ministry of Health stated in Berlin that the companies' decisions to disinvest are regrettable and highlight the serious challenges posed, particularly by U.S. pharmaceutical policy.

American pharmaceutical company Eli Lilly announced earlier this week that it will halve a planned investment of 2.5 billion euros for a new site in Alzey, Rhineland-Palatinate. The company cited austerity measures proposed by the German government in the healthcare sector as the reason. German pharmaceutical firm Boehringer Ingelheim also stated it would halt planned investments totaling 900 million euros in Germany.

Boehringer Ingelheim cited difficult conditions in Germany, the government's savings targets, and pressure from the United States as reasons for its decision. The company has entered into an agreement with the U.S. government to receive exemption from pharmaceutical tariffs in return for investments in America.

Federal Minister of Health Nina Warken (CDU) aims to relieve statutory health insurers of 16.3 billion euros by 2027 through the "Contribution Rate Stabilization Act" to prevent increases in additional contributions. The plans also include stricter savings requirements for the pharmaceutical industry, such as increasing manufacturer rebates to health insurers from the current 7 percent of the list price to approximately 20 percent by 2030.

The pharmaceutical industry has sharply criticized the government's plans, arguing they harm Germany's attractiveness as an investment location and undermine the government's goal of strengthening the pharmaceutical sector as a key industry.